Literature DB >> 29401003

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Izak Faiena1, Stuart Holden1, Mathew R Cooperberg1, Stuart Holden1, Howard R Soule1, Jonathan W Simons1, Todd M Morgan1, David F Penson1, Alicia K Morgans1, Maha Hussain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29401003      PMCID： PMC6804825          DOI： 10.1200/JCO.2017.76.4050

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  59 in total

1.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

2.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Authors:  Peter R Carroll; J Kellogg Parsons; Gerald Andriole; Robert R Bahnson; Erik P Castle; William J Catalona; Douglas M Dahl; John W Davis; Jonathan I Epstein; Ruth B Etzioni; Thomas Farrington; George P Hemstreet; Mark H Kawachi; Simon Kim; Paul H Lange; Kevin R Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M Morgan; Kelvin A Moses; Robert B Nadler; Michael Poch; Chuck Scales; Terrence M Shaneyfelt; Marc C Smaldone; Geoffrey Sonn; Preston Sprenkle; Andrew J Vickers; Robert Wake; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2016-05       Impact factor: 11.908

3.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

Authors:  Matthew R Cooperberg; Peter R Carroll
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

4.  Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Authors:  Paul F Pinsky; Philip C Prorok; Kelly Yu; Barnett S Kramer; Amanda Black; John K Gohagan; E David Crawford; Robert L Grubb; Gerald L Andriole
Journal:  Cancer       Date:  2016-12-01       Impact factor: 6.860

5.  Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.

Authors:  Bimal Bhindi; Muhammad Mamdani; Girish S Kulkarni; Antonio Finelli; Robert J Hamilton; John Trachtenberg; Alexandre R Zlotta; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Neil E Fleshner
Journal:  J Urol       Date:  2014-12-03       Impact factor: 7.450

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

8.  Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.

Authors:  Amir Qaseem; Michael J Barry; Thomas D Denberg; Douglas K Owens; Paul Shekelle
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

9.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

10.  Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.

Authors:  Renea A Taylor; Michael Fraser; Julie Livingstone; Shadrielle Melijah G Espiritu; Heather Thorne; Vincent Huang; Winnie Lo; Yu-Jia Shiah; Takafumi N Yamaguchi; Ania Sliwinski; Sheri Horsburgh; Alice Meng; Lawrence E Heisler; Nancy Yu; Fouad Yousif; Melissa Papargiris; Mitchell G Lawrence; Lee Timms; Declan G Murphy; Mark Frydenberg; Julia F Hopkins; Damien Bolton; David Clouston; John D McPherson; Theodorus van der Kwast; Paul C Boutros; Gail P Risbridger; Robert G Bristow
Journal:  Nat Commun       Date:  2017-01-09       Impact factor: 14.919
View more
  3 in total

Review 1.  Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.

Authors:  Adam B Weiner; Oluwarotimi S Nettey; Alicia K Morgans
Journal:  Curr Treat Options Oncol       Date:  2019-07-09

2.  Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction.

Authors:  Youdong Lin; Guihua Liu; Chun Liu; Hui Xie; Xiaoxian Wang; Yudian Huang; Long Jin; Huidan Chen
Journal:  Cancer Med       Date:  2022-03-15       Impact factor: 4.711

3.  Testing of a Tool for Prostate Cancer Screening Discussions in Primary Care.

Authors:  Anita D Misra-Hebert; Grant Hom; Eric A Klein; Janine M Bauman; Niyati Gupta; Xinge Ji; Andrew J Stephenson; J Stephen Jones; Michael W Kattan
Journal:  Front Oncol       Date:  2018-06-28       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.